Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04491370 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 15, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Aug 15, 2024 to Aug 15, 2026
    • Study completion date: Aug 15, 2025 to Aug 15, 2027
    • Site contact updated
    v4
  2. Primary completion date: Aug 15, 2023 to Aug 15, 2024
    • Study completion date: Aug 15, 2024 to Aug 15, 2025
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 15, 2020 to Aug 1, 2021
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
New York Medical College
24 trials monitored
See all monitored trials
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
Follicular Lymphoma
347 trials monitored
See 28 trials at risk
and 2 more diseases
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.
Trial Details
NCT Number NCT04491370
Lead Sponsor New York Medical College
Conditions
(from sponsor)		 B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Non-Hodgkin Lymphoma, Richter Syndrome +1 more
Related terms Burkitt Lymphoma, Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov